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Abstract 
 
This study examined the cardiac and vasomotor responses to submaximal handgrip exercise and 
beta-adrenergic control in carriers (n = 6) and non-carriers (n = 4) of a genetic variant of 
adenylyl cyclase 6 (AC S674). Rhythmic handgrip contractions (1 minute bout; 2 second 
contraction-relaxation period) were performed at three different intensities (20, 40, and 60% of 
maximal voluntary contraction force) to test the vasodilatory response to exercise. Additionally, 
two 5 minute infusions of isoproterenol (0.01 and 0.02 µg·kg
-1
·min
-1
 diluted in 5% dextrose) and 
one 10 minute infusion of propranolol (0.1 mg·kg
-1
 diluted in 0.9% saline) were used to examine 
beta-adrenergic mediated cardiovascular responses. Ascending aorta and brachial artery mean 
blood flow velocities (pulsed Doppler ultrasound) and brachial artery blood pressure (Finometer) 
were continuously measured during handgrip and pharmacological protocols. Vascular 
mechanics of the forearm were calculated using a three-element lumped windkessel model. At 
baseline, AC S674 carriers have decreased systemic vascular conductance and forearm vascular 
bed compliance, as well as increased pulse pressure. However, AC S674 carriers did not exhibit 
altered cardiac or vasomotor control during handgrip exercise, isoproterenol infusion, or 
propranolol infusion. These results indicate that expression of the dysfunctional genetic variant 
AC S674 has profound effects on systemic hemodynamics at rest. Chronic elevation in vascular 
contractile state may result in vascular stiffening and enhanced pulse pressures with detrimental 
long-term consequences for cardiovascular health.   
iii 
 
Co-Authorship Statement 
 
Dr. Rosemary Craen: Dr. Craen prepared and administered pharmacological agents. 
 
Dr. Sophie Lalande: Dr. Lalande assisted with data collection and conducted echocardiograms on 
participants. 
 
Dr. Peter Mack: Dr. Mack prepared and administered pharmacological agents. 
 
Adam McIntyre: Mr. McIntyre performed all genomic DNA analysis and assisted with writing 
Section 3.5.4. 
 
T. Dylan Olver: Mr. Olver assisted with data collection and performed all aortic ultrasound 
measurements. Mr. Olver also assisted with data analysis and the editing of this document. 
 
Dr. Maxim Rachinsky: Dr. Rachinsky prepared and administered pharmacological agents. 
 
Dr. J. Kevin Shoemaker: Dr. Shoemaker supervised study design, data analysis, and the writing 
of this document.  
 
 
 
  
iv 
 
Acknowledgements 
 
 This is really hard for me to do. There are too many people to thank and not enough 
space to get to every one of you. However, I will try my best.  
I have been a student at The University of Western Ontario for the better part of the last 
decade – and yes, I will still refer to it as UWO. It still feels strange wrapping up this document 
and ending my tenure as a student at UWO. I am also pretty sure there are some people who will 
be glad to finally get rid of me too. Well, University Hospital is not far from Thames Hall, so 
you are not entirely rid of me yet. How do you like them apples?  
In all seriousness, I would not be writing this section if it were not for a special group of 
individuals who have helped me reach this point. First and foremost, I need to thank my family, 
especially my parents (Tom and Jan). In addition to being responsible for my existence, I would 
like to thank you for always believing in me and providing me with guidance, criticism, and 
inspiration. Amanda, you are a wonderful sister. Jack, sit. Good boy. I could not have done this 
without any of you.  
 To my UWO friends, where would I be without you? You are all wonderful and amazing. 
Thank you for being the best friends I could ever ask for. There is also no better group of lab 
mates than the NVRL team (Dylan, Mark, Chantelle, Torri, Tamara, Charlotte, Nicole, Maria, 
Danielle, Jacquie, Katelyn, Carly, Carolyn, Carol, and Arlene). There is no other group of people 
who I would rather eat copious amounts of cake and pizza with.   
Last, but not least, I would like to thank Dr. Kevin Shoemaker. I cannot express how 
grateful I am for giving me the opportunity to come into your lab in 2010. You have provided me 
with all the necessary tools to be an effective – and hopefully successful – researcher. Your 
passion for research and teaching are second to none. It has truly been an honour to work under 
your supervision. Although I am not too sure what the lab is going to do without me, just 
kidding.  
 
 
 
In the immortal words of Douglas Adams, “Don’t panic.” 
  
v 
 
Table of Contents 
 
Abstract ........................................................................................................................................... ii 
Co-Authorship Statement............................................................................................................... iii 
Acknowledgements ........................................................................................................................ iv 
List of Abbreviations ................................................................................................................... viii 
List of Tables ................................................................................................................................. ix 
List of Figures ................................................................................................................................. x 
List of Appendices ......................................................................................................................... xi 
Chapter 1 ......................................................................................................................................... 1 
1. Introduction ............................................................................................................................. 1 
1.2 Purpose .................................................................................................................................. 2 
1.3 Hypothesis ............................................................................................................................. 2 
Chapter 2 ......................................................................................................................................... 3 
2. Literature Review .................................................................................................................... 3 
2.1 Blood Pressure....................................................................................................................... 3 
2.1.2 Systemic Vasculature & Blood Pressure ........................................................................ 3 
2.1.3 Blood Pressure and Blood Flow ..................................................................................... 4 
2.2   Arterial Blood Flow ............................................................................................................ 5 
2.2.1 The Arterial Windkessel ................................................................................................. 6 
2.2.2 The RCKL Model ........................................................................................................... 6 
2.2.3 Vascular Bed Mechanics & Vasomotor Control ............................................................ 8 
2.3 Vasodilation and Hyperemia ................................................................................................. 8 
2.3.1 Adenylyl Cyclase ............................................................................................................ 9 
2.3.2 Adenylyl Cyclase Isoforms .......................................................................................... 10 
2.3.3 Adenylyl Cyclase: Genetic Variants............................................................................. 11 
2.3.4 Adenylyl Cyclase 6 Variant .......................................................................................... 11 
2.3.5 Beta-Adrenergic Control .............................................................................................. 12 
2.4 Blood Flow Measurements.................................................................................................. 12 
2.4.1 Doppler Ultrasound ...................................................................................................... 12 
2.5 Brachial Artery Pressure Measurements ............................................................................. 13 
Chapter 3 ....................................................................................................................................... 14 
vi 
 
3. Methodology ............................................................................................................................. 14 
3.1 Ethical Approval ................................................................................................................. 14 
3.2 Subjects ............................................................................................................................... 14 
3.3 Genomic DNA Analysis ..................................................................................................... 14 
3.4 Experimental Design ........................................................................................................... 15 
3.4.1 Hemodynamics ............................................................................................................. 15 
3.4.2 Ultrasound .................................................................................................................... 16 
3.4.3 Handgrip Exercise ........................................................................................................ 16 
3.4.4 Cardiac and Vasomotor Control ................................................................................... 17 
3.5 Data Analysis ...................................................................................................................... 17 
3.5.1 Stroke Volume .............................................................................................................. 17 
3.5.2 Forearm Blood Flow ..................................................................................................... 18 
3.5.3 Vascular Bed Mechanics .............................................................................................. 18 
3.5.4 Statistical Analysis ....................................................................................................... 19 
Chapter 4 ....................................................................................................................................... 20 
4. Results ....................................................................................................................................... 20 
4.1 Baseline Assessment ........................................................................................................... 20 
4.1.1 Anthropometric Measurements .................................................................................... 20 
4.1.2 Hemodynamic Measurements ...................................................................................... 21 
4.1.3 Forearm Vascular Bed Mechanics ................................................................................ 21 
4.2 Handgrip Exercise ............................................................................................................... 22 
4.2.1 Forearm Blood Flow ..................................................................................................... 22 
4.2.2 Mean Arterial Pressure ................................................................................................. 22 
4.2.2 Forearm Vascular Conductance .................................................................................... 22 
4.3 Cardiac and Vasomotor Control .......................................................................................... 29 
4.3.1 Heart Rate ..................................................................................................................... 29 
4.3.2 Stroke Volume .............................................................................................................. 29 
4.3.3 Cardiac Output .............................................................................................................. 29 
4.3.4 Mean Arterial Pressure ................................................................................................. 29 
4.3.5 Systemic Vascular Conductance .................................................................................. 30 
4.3.6 Forearm Blood Flow ..................................................................................................... 30 
4.3.7 Forearm Vascular Conductance .................................................................................... 30 
vii 
 
4.3.8 Forearm Vascular Bed Mechanics ................................................................................ 30 
Chapter 5 ....................................................................................................................................... 44 
5. Discussion ............................................................................................................................. 44 
5.1 Baseline ............................................................................................................................... 44 
5.1.1 Methodological Considerations .................................................................................... 46 
5.2 Handgrip Exercise ............................................................................................................... 46 
5.3 Beta-adrenergic Control ...................................................................................................... 48 
5.4 Limitations .......................................................................................................................... 48 
5.5 Conclusion and Perspective ................................................................................................ 49 
References ..................................................................................................................................... 50 
Appendices .................................................................................................................................... 56 
Curriculum Vitae .......................................................................................................................... 59 
 
 
 
 
  
viii 
 
List of Abbreviations 
 
 AC    Adenylyl Cyclase 
 
 AC S674   Adenylyl Cyclase 6 genetic variant 
 
 ATP    Adenosine Triphosphate 
 
BP    Blood Pressure (mmHg) 
 
 C    Compliance (ml·mm Hg
-1
·100ml
-1
) 
 
 cAMP    cyclic Adenosine Monophosphate 
 
CO Cardiac Output CO (l·min
-1
·m
2
) 
 
DBP    Diastolic Blood Pressure (mm Hg) 
 
FBF Forearm Blood Flow (ml·min
-1
·100ml
-1
) 
 
HR Heart Rate (beats·min
-1
) 
 
K Viscoelasticity (mm Hg·ml
-1
·min
-1
) 
 
L Inertia (mm Hg·ml
-1
·min
2
) 
 
MAP Mean Arterial Pressure (mm Hg) 
 
PP Pulse Pressure (mm Hg) 
 
R Resistance (mm Hg·ml
-1
·min
-1
) 
 
SBP Systolic Blood Pressure (mm Hg) 
 
SV Stroke Volume (ml·min
-1
) 
 
SVC Systemic Vascular Conductance  
(ml·min
-1
·100ml
-1
·mm Hg
-1
)  
ix 
 
List of Tables 
 
Table 4.1 Anthropometric measurements………………………………………………….…20 
Table 4.2 Baseline hemodynamic characteristics…………………………………………….21 
Table 4.3 Baseline forearm vascular bed mechanics..………………………………………..21 
 
 
  
x 
 
List of Figures 
 
Figure 2.1 The RCKL model……………….………………………………………………….….7 
Figure 2.2 Adenylyl cyclase and vascular smooth muscle….…………………………………….9 
Figure 2.3 Adenylyl cyclase enzyme…………………………………………………………….10 
Figure 3.1 Handgrip exercise protocol…………………………………………………………..16 
Figure 4.1FBF, MAP, and FVC response to 20% handgrip……………………………………..23 
Figure 4.2 ΔFBF and ΔFVC to 20% handgrip…………………………………………………...24 
Figure 4.31FBF, MAP, and FVC response to 40% handgrip..…………………………………..25 
Figure 4.4 ΔFBF and ΔFVC to 40% handgrip…………………………………………………...26 
Figure 4.5 FBF, MAP, and FVC response to 60% handgrip…………………………………….27 
Figure 4.6 ΔFBF and ΔFVC to 60% handgrip…………………………….……………………..28 
Figure 4.7 HR responses to isoproterenol infusion………………………………………………31 
Figure 4.8 SV responses to isoproterenol infusion………………………………………………32 
Figure 4.9 CO responses to isoproterenol infusion………………………………………………33 
Figure 4.10 MAP responses to isoproterenol infusion.......………………………………………34 
Figure 4.11SVC responses to isoproterenol infusion……………………………………………35 
Figure 4.12 FBF responses to isoproterenol infusion…....………………………………………36 
Figure 4.13 FVC responses to isoproterenol infusion……………...……………………………37 
Figure 4.14 Cardiac responses to propranolol infusion.....………………………………………38 
Figure 4.15 Systemic responses to propranolol infusion...………………………………………39 
Figure 4.16 Forearm vascular responses to propranolol infusion………………………………..40 
Figure 4.17 Forearm vascular bed mechanic responses to isoproterenol………………………..41 
Figure 4.18 Forearm vascular bed mechanic responses to propranolol (R and C)........................42 
Figure 4.19 Forearm vascular bed mechanic responses to propranolol (K and L)........................43 
 
 
  
xi 
 
List of Appendices 
 
Appendix 1A: Statistical analysis of 20% handgrip exercise……………………………………56 
Appendix 1B: Statistical analysis of 40% handgrip exercise……………………………………56 
Appendix 1C: Statistical analysis of 60% handgrip exercise……………………………………56 
Appendix 2: Statistical analysis of isoproterenol………………………………………………...56 
Appendix 3: Copyright Permissions……………………………………………………………..57 
Appendix 4: Use of Human Participants – Ethics Approval Notice……………………………..58 
 
1 
 
Chapter 1 
 
1. Introduction 
 
The human cardiovascular system is a progression of vessels arranged in parallel and in 
series. Oxygenated blood is ejected from the left ventricle into the aorta and dispersed through 
arteries, arterioles and capillaries of the systemic circulation before venous return to the right 
atrium. The flow of blood to any tissue in the human body depends on perfusion pressure (i.e. 
mean arterial pressure) and vascular tone (i.e. resistance; Delp, 1998). Perfusion pressure is 
regulated by feedback control systems that rely on autonomic nerves and circulating hormones 
(Dampney, 2002). Vascular tone is influenced by sympathetic vasomotor nerve activity, 
circulating vasoactive hormones, and local factors such as metabolites and endothelial factors 
(Clifford, 2011). The fundamental purpose of cardiovascular control is to maintain homeostasis 
by matching blood flow to the metabolic demands of all tissues within the body. 
Blood flow to contracting skeletal muscle increases rapidly at the onset of voluntary 
submaximal exercise to meet the metabolic requirements of that muscle. This exercise hyperemic 
response is achieved through an increase in cardiac output and vasodilation of the exercising 
skeletal muscle vascular bed (Dampney, 2002). Cardiac output increases due to elevations in 
heart rate and stroke volume (Åstrand, 1964; Hermansen, 1970; Eriksen, 1990; Rowell, 1993). 
However, despite over 100 years of research, summarized in several reviews (Saltin, 1998; 
Clifford, 2004; Joyner, 2007; Saltin, 2007, Clifford, 2011), considerable uncertainty remains 
regarding the vasodilatory mechanisms responsible for vasomotor control and blood pressure 
regulation during exercise.  
Adenylyl cyclase (AC) is a G-protein-coupled enzyme that reduces intracellular calcium 
within vascular smooth muscle. Adenylyl cyclase catabolizes intracellular ATP into cyclic AMP 
(cAMP) via beta-adrenergic stimulation of the Gαs protein. Elevated levels of cAMP produce a 
decrease in intracellular calcium and subsequent relaxation of vascular smooth muscle. Recently, 
a dysfunctional variant of the adenylyl cyclase 6 isoform (AC S674) has been identified in 
humans (Gros, 2005) Expression of the AC S674 variant correlates with greater venous dilation 
in response to beta-adrenergic stimulation, and increased post-exercise hyperemia to volitional 
handgrip exercise (Gros, 2007; Hodges, 2010). Therefore, the enhanced vasodilatory capacity of 
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AC S674 carriers may provide further insight into the mechanisms responsible for exercise 
hyperemia. 
Adenylyl cyclase is activated via β1 (cardiac) and β2 (vascular smooth muscle) receptor 
stimulation and therefore contributes to neurogenic vasomotor control. Vascular resistance, or its 
inverse of conductance, reflects the state of vascular contraction and alters blood flow to a 
vascular bed through changes in arterial diameter. However, the concept of vascular resistance 
involves steady state flow and does not account for the pulsatile nature of blood flow (Zamir, 
2007). Recent evidence has suggested that compliance is an independent variable that deserves 
consideration when examining vasomotor regulation in skeletal muscle (Zamir, 2007; Frances, 
2011). The study of vascular bed mechanics is integral to understanding vasomotor control and 
blood flow to skeletal muscle. 
 
1.2 Purpose 
 
The primary purpose of this study was to investigate the cardiac and vasomotor responses to 
beta-adrenergic control in carriers and non-carriers of the variant AC S674. The second purpose 
of this study was to examine the impact of the AC S674 variant to vasomotor control during 
submaximal handgrip exercise.  
 
1.3 Hypothesis 
 
This study tested the hypothesis that individuals who express the AC S674 variant will: 1) 
express increased vasodilatory and tachycardia response to beta-adrenergic activation, and; 2) 
have a greater vasodilatory response to handgrip exercise.   
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Chapter 2 
 
2. Literature Review 
 
2.1 Blood Pressure 
  
Blood pressure at any location of the vasculature encompasses three components: 1) 
static pressure that is related to the volume of blood within the vascular system at zero flow; 2) 
hydrostatic pressure caused by the force of gravity and referred to as pgh, where p is fluid 
density, g is the acceleration due to gravity, and h is the height of the hydrostatic column, and; 3) 
dynamic pressure generated by the heart is equal to blood flow x resistance (Rowell, 1993).  The 
last component alone is responsible for the movement of blood and is commonly referred to as 
‘blood pressure’.  
  
2.1.2 Systemic Vasculature & Blood Pressure 
 
The rhythmic beating of the left ventricle creates a pulsatile pressure waveform that is 
propagated throughout the systemic vasculature. This pressure waveform is regulated by arterial 
structure and mechanical components (i.e. elastin and collagen). Each region of the systemic 
vasculature serves a different function: 1) the large central elastic arteries (e.g. aorta, carotid etc.) 
act as a cushioning reservoir that stores blood during systole and eject blood to the periphery 
during diastole; 2) muscular arteries (e.g. brachial, femoral) serve as long conduits to transport 
blood to the periphery and organs, and; 3) high resistance arterioles that maintain mean arterial 
pressure and modulate steady state blood flow to vascular beds. 
As the pressure waveform generated by the heart travels to the periphery, local systolic 
and pulse pressures increase. However, diastolic and mean pressures decrease when moving 
from central to peripheral vascular segments due to the progressive increase in arterial stiffness, 
and arterial branching that reduces overall vascular resistance (Nichols & O'Rourke, 2005). The 
total pressure waveform recorded at any location of the arterial tree is the sum of the forward 
wave produced by left ventricular ejection, and the backward traveling wave that is reflected at 
peripheral sites (Agabiti-Rosei, 2007).  Potential wave reflection sites include branching points, 
areas of altered arterial elastance, and the high-resistance arterioles (Nichols & O’Rourke, 2005). 
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Thus, the pressure wave becomes increasingly altered as it moves farther away from the aorta in 
the circulation.  
 
2.1.3 Blood Pressure and Blood Flow 
 
 The systemic arterial tree acts as a closed loop circuit consisting of thousands of 
cylindrical tubes. As such, many scientists began to apply the principles of fluid mechanics to 
better understand the relationship between blood pressure and flow. Jean Louis Poisseuille 
(1846) was the first hemodynamic scientist to establish that flow in a tube was related to the 
fourth power of the tube’s internal radius. Poiseuille’s Law is: 
      
    
   
 
where P1 – P2 is the pressure change in the tube, Q is the volumetric flow rate, µ is the dynamic 
viscosity, L is the length of the tube, and r is the radius of the tube.  
Additionally, Georg Simon Ohm (1827) stated that the current through a conductor 
between two points is directly proportional to the potential difference across two points. The 
inclusion of resistance to this principle ended with the development of Ohm’s Law: 
  
 
 
 
where I is the current through the conductor, V is the potential difference measured across the 
conductor, and R is the resistance of the conductor. Applied to the cardiovascular system, Ohm’s 
law is transformed: 
  
     
 
 
where Q is the volumetric flow rate of blood, P1 – P2 is the pressure drop across the artery, and R 
is the resistance to blood flow in the artery. Therefore, a direct relationship can be made between 
vascular contractile state and blood flow in the cardiovascular system.  
Due to Poisseuille and Ohm’s equations consisting of similar variables, Poisseuille’s law 
can be altered to the following: 
  
   
   
 
where R is the resistance to blood flow in the artery, µ is the dynamic viscosity of blood, L is the 
length of the vessel, and r is the radius of the vessel. In fluid mechanics pressure is the driving 
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force behind flow. Blood flow will travel from areas of high pressure (arteries) to areas of low 
pressure (veins). Furthermore, changes in artery radius will create the largest flow responses in 
the vasculature. Dilation in an artery or vascular bed will reduce resistance thereby increasing 
blood flow. 
 Vascular conductance is the inverse of resistance and is defined as the ability for a fluid 
to flow through a conduit per unit pressure difference:  
   
 
  
 
where R is the resistance to blood flow in the artery, and VC is the conductance of blood through 
the artery. When substituted into Ohm’s equation for blood flow, the resultant equation is: 
    
 
     
 
where VC is the conductance of blood through the artery, Q is the volumetric flow rate of blood, 
and P1 – P2 is the pressure drop across the artery. Similar to resistance, an increase in arterial 
diameter (thereby decreasing resistance and increasing flow) will produce a large change in 
vascular conductance.  
 The study of hemodynamics has elucidated the strong relationship between pressure and 
flow. Pressure is the driving force behind flow in the arterial system and especially through 
vascular beds. During exercise, muscular contractions squeeze blood out of the venous 
capacitance vessels thereby enhancing the arterial- venous (P1 – P2) pressure difference and 
along with elevated vascular conductance (through arterial vasodilation) drive flow through the 
vascular bed (Rowell, 1993).  
 
2.2   Arterial Blood Flow 
 
 The physics that govern Poisseuille and Ohm’s laws concern oscillatory flow through 
rigid tubes of constant diameters.  However, arteries are viscoelastic tubes whose diameters 
fluctuate with pulsating pressures that are generated by pulsatile flows from the left ventricle 
(Sonesson, 1994).  As such, the arterial system has been modeled in a number of different ways 
to study hemodynamics: tube models, anatomically based distribution models, and lumped 
models (Westerhof, 2009). The arterial Windkessel model was first proposed by Stephen Hales 
to account for the pulsatile nature of blood flow. The arteries act as a cushion that converts 
pulsatile flow from the heart into steady state flow through vascular beds. Thus, the Windkessel 
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model is a lumped model that describes the pressure-flow relationship of the whole arterial 
system from its entrance.  
 
2.2.1 The Arterial Windkessel 
 
The first arterial Windkessel model was developed by Otto Frank to determine the 
resistance (R, total peripheral resistance) and compliance (C) of the systemic vascular bed based 
on aortic measurements (Westerhof, 2009). However, it is now known that the pulsatile 
mechanics of flow through a vascular bed are additionally influenced by viscoelasticity (K) and 
inertance (L; Zamir 2007). Together, R (resistance due to viscous drag at the vessel wall); C, and 
K (due to viscoelastic opposition to stretch of the vessel wall); and L (inertia of the blood and 
vessel wall) compose a modified four element lumped Windkessel used to predict flow in a 
peripheral vascular bed (Zamir, 2007; Zamir, 2009; Frances, 2011).  
 
2.2.2 The RCKL Model 
 
Flow into a vascular bed relies on both steady state (R) and oscillatory (C, K, and L) 
components (Zamir, 2009). R is obtained by simultaneously measuring mean pressure and mean 
flow at the point of entry to a vascular bed (Zamir, 2009). Additionally, the values of C, K, and L 
are calculated from the simultaneous measurement of oscillatory pressure and flow at the 
vascular bed entry point (Zamir, 2009). For a given set of values (C, K, and L), the model 
predicts a flow wave that would be produced by a measured pressure wave during pulsatile flow 
(Zamir, 2007). The most accurate model can be determined by the lowest error value that is 
determined by the sum of the differences squared between the two waveforms at each point 
along the wave (Nielson, 2011). The process is automated using MATLAB software and 
techniques of fast Fourier transform (Brigham, 1988; Figure 2.1).  
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A.                                                                                   B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C.                                                                        D. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 The RCKL Model A. ECG, pressure, and flow channels; B. Mean pressure waveform 
(top) and mean flow waveform (bottom); C. R (mean pressure and flow) is measured in parallel 
to C, K, and L (oscillatory pressure and flow) at the vascular bed point of entry; D. Predicted 
flow wave (dashed-line) and measured flow wave (solid) with values of R, C, K, and L 
displayed.  
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2.2.3 Vascular Bed Mechanics & Vasomotor Control 
 
 The steady state component of blood flow regulation to skeletal muscle vascular beds is 
controlled by vascular resistance (or its inverse of vascular conductance) and perfusion pressure. 
However, arterial compliance plays an integral role in the mechanics of pulsatile flow. 
Compliance reflects the elasticity of the arterial wall, but can be affected by vascular smooth 
muscle (VSM) contractile state and, therefore neural innervation (Grassi, 1995). For example, 
relaxation of VSM has been shown to cause increased compliance in the brachial artery and 
forearm (Fitchett, 1984; Safar, 1987). Recent research from our laboratory has confirmed the 
importance of compliance as a regulatory variable in vasomotor control. Specifically, Zamir 
(2007) examined the forearm vascular bed and reported increased compliance with arm elevation 
(relative to the heart), and decreased compliance as a result of lower body negative pressure or a 
cold pressor test. In a follow-up study conducted by Frances (2011), adrenergic activation via 
noradrenaline infusion decreased forearm vascular bed compliance. In addition to alpha 
adrenergic receptors, beta adrenergic receptors contribute a dilatory stimulus to VSM (Garovic, 
2002; Eisenach, 2004). Beta-adrenergic control exerts its effect through the adenylyl cyclase 
enzyme. Very little research has been conducted on the role of this enzyme in either vasomotor 
responses to exercise or vascular mechanics.  
 
2.3 Vasodilation and Hyperemia 
 
 Numerous reviews have examined the vasodilatory mechanisms responsible for exercise 
hyperemia ( Saltin, 1998; Clifford, 2004; Joyner, 2007; Saltin, 2007; Clifford 2011). The 
classical view is that there is an interaction between numerous vasodilatory mechanisms (lactate, 
H
+
 ions, oxygen, ATP and adenosine, nitric oxide, prostaglandins, and endothelial derived 
hyperpolarizing factor) released via skeletal muscle, endothelium, and erythrocytes that 
contribute to hyperemia. Essentially, vasodilation is the result of processes decreasing 
concentrations of intracellular calcium within vascular smooth muscle cells (Clifford, 2004). The 
enzyme adenylyl cyclase is a regulator of intracellular calcium within vascular smooth muscle 
(Figure 2.2). However, only one study to date, from our group, has examined the effects of 
adenylyl cyclase on exercise hyperemia in humans (Hodges, 2010). 
9 
 
 
 
 
 
Figure 2.2 Adrenergic mediated pathways of adenylyl cyclase in a vascular smooth muscle cell. 
β2 receptor activation activates adenylyl cyclase to convert ATP into cAMP producing a decrease 
in intracellular calcium, inhibition of Phopholipase C, relaxation of vascular smooth muscle, and 
a consequent arterial vasodilation. (DAG, diacylglycerol; IP3, inositol triphosphate; SR, 
sarcoplasmic reticulum; reprinted with permission from K. Shoemaker). 
 
2.3.1 Adenylyl Cyclase 
 
Adenylyl cyclase (AC) is a ubiquitous enzyme that catalyses the conversion of 
intracellular ATP to cAMP. The adenylyl cyclases are large (1 080 – 1 248 amino acids) 
polypeptides that cross the plasma membrane 12 times in two cassettes of six transmembrane 
spanning domains; each individual cassette is followed by a large cytosolic domain (Figure 2.3; 
Cooper, 1995; Patel, 2001). 
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Figure 2.3 Schematic of the proposed structure for membrane bound adenylyl cyclase. The AC 
enzyme is composed of two transmembrane regions (M1 and M2) combined with two 
cytoplasmic domains (C1 and C2; Patel, 2001; reprinted with permission). 
 
 The structure of AC allows for extracellular (via αi, αs, and βγ subunits of G protein-
coupled receptors) and intracellular (via protein kinases, phosphatases, calcium, and 
calcium/calmodulin) interactions to occur (Cooper, 1995; Hanoune, 2001; Gros, 2005). The two 
cytosolic domains of AC constitute the catalytic site and are regulated by varying concentrations 
of ions such as calcium and magnesium (Hurley, 1999). Due to these many interactions, AC has 
been proposed to be the rate-limiting step in the G protein-coupled receptor-signaling cascade 
(Ostrom, 2012).  
 
2.3.2 Adenylyl Cyclase Isoforms 
 
 Currently, there are nine membrane bound isoforms (AC1-9) and one soluble form of 
mammalian AC that have been characterized and separated into three different groups (Group 1: 
AC1, AC3, AC8; Group 2: AC2, AC4, AC7; and Group 3: AC5 and AC6; Defer, 2000; 
Hanoune, 2001; Patel, 2001). The additional soluble AC is the predominant form in mammalian 
sperm and is classified separately (Wuttke, 2001). All of the AC isoforms share a large sequence 
homology in the primary structure of the catalytic site. However, the catalytic sites of each 
isoform have a specific pattern of regulation by G proteins, calcium/calmodulin, and protein 
kinases (Defer, 2000; Hanoune, 2001; Ostrom, 2012). These distinct properties allow AC 
isoforms to play an interpretive role in signal transduction as opposed to a linear activation 
pathway of G protein-coupled receptors. Therefore, external signal integration from G protein-
coupled receptors depends on the properties and relative level of isoform expression in tissues 
(Cooper, 1995; Defer, 2000). Although there are many isoforms and regulatory processes, the 
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resultant end product of all adenylyl cyclase isoforms is the same (i.e. an increase in intracellular 
cAMP; Ostrom, 2012). 
 
2.3.3 Adenylyl Cyclase: Genetic Variants 
 
 Genetic variants have been described for a variety of G proteins and G protein-coupled 
receptors linked to adenylyl cyclase (Rana, 2001). Expression of these genetic variants leads to 
alterations in receptor-mediated activation of adenylyl cyclase in addition to alterations in 
downstream effector pathways. Currently, the identification of dysfunctional genetic variants has 
been limited to isoforms AC3, AC6 and AC9 (Ikoma, 2003; Small, 2003). The AC6 isoform is 
the predominant adenylyl cyclase in the human adult left ventricle and is a critical regulator in 
vascular smooth muscle (Wang, 2004; Gros, 2006). Furthermore, the expression of a genetic 
variant of AC6 that alters AC6 function could lead to modified vascular adenylyl cyclase-
mediated effects (Gros, 2007). 
 
2.3.4 Adenylyl Cyclase 6 Variant 
 
 The AC6 variant results from a single nucleotide polymorphism in intron 17 of the gene 
that codes for the normal AC6 isoform (Gros, 2005). This variant was originally discovered in a 
population of Japanese individuals (Ikoma, 2003). Further research concluded that a missense 
mutation occurred at amino acid 674 within the AC6 catalytic domain (Gros, 2005). This AC6 
variant has a genotypic frequency of approximately 6% in Caucasians and is referred to as AC 
S674 (Gros, 2005). 
 Recent research has concluded that AC S674 is a hyperfunctional variant compared to the 
more common wild type AC A674. Gene transfer of AC S674 to rat vascular smooth muscle 
cells resulted in increased AC activity and arborization (Gros, 2007). Isolated mononuclear 
leukocyte cells from humans expressing AC S674 displayed significantly increased AC activity 
and AC-mediated cell retraction (Gros, 2007). Additionally, the expression of AC S674 in 
humans correlated with: 1) increased AC enzymatic activity and; 2) enhanced AC-mediated 
vasodilation to isoproterenol as measured by a dorsal vein linear variable differential transformer 
(Gros, 2007).  In regards to blood flow control, human carriers of AC S674 expressed greater 
post-exercise forearm blood flow responses to isometric handgrip exercise (Hodges, 2010). 
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However, the direct effect of AC S674 stimulation or inhibition on human cardiac and vasomotor 
control remains to be elucidated.  
 
2.3.5 Beta-Adrenergic Control 
 
 Adenylyl cyclase is stimulated when the heterotrimeric G protein, Gαs, is activated by 
epinephrine or norepinephrine binding to β1 or β2 adrenergic receptors (Saucerman, 2003). The 
activation of β1 and, to a lesser extent, β2 receptors in the heart produces an overall increase in 
cardiac output. The increase in cardiac output is a combination of increased cardiac stimulation 
(β1; positive inotropy, lusitropy, and chronotropy) and myocardial contractility (β2; Katz, 2011). 
As mentioned previously (Figure 2.2), the activation of β2 receptors in VSM produces a 
relaxation of smooth muscle and subsequent arterial vasodilation. Conversely, beta-adrenergic 
antagonists prevent epinephrine and norepinephrine from binding to β1 and β2 receptors. When 
this occurs, AC is deactivated and results in diminished physiological responses (i.e. decreased 
heart rate; Katz, 2011). Thus, beta-adrenergic mediated regulation of AC is imperative for both 
cardiac and vasomotor control. 
 
2.4 Blood Flow Measurements 
 
 Blood flow to a vascular bed increases in proportion to the metabolic demands of the 
active muscle tissue (Andersen & Saltin, 1985). Measurement of arterial inflow is necessary to 
accurately assess the hyperemic response in exercising limbs. Regional limb blood flow 
measurements have previously been conducted via electromagnetic flow meters, 
plethysmography, intravascular indicators (e.g. thermodilution), Doppler ultrasound, and 
magnetic resonance imaging (Rådegran, 1999). Recently, Doppler ultrasound has become the 
preferred modality to measure blood flow to exercising limbs.  
 
2.4.1 Doppler Ultrasound 
  
Ultrasound is defined as a mechanical vibration with a frequency ( f ) above the range of 
human hearing. Ultrasound measurements calculate the Doppler frequency shift (Δf ) that occurs 
as sound waves are reflected by erythrocytes (Gill, 1979). More simply defined, Δf is the 
transmitted frequency (fT) minus the received frequency (fR): 
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Thus, blood velocity can be described as positive (towards the transducer) or negative (away 
from the transducer). The Doppler equation is used to detect blood velocity:  
   
          
 
 
where Δf  is the change in frequency received by the transducer, v is the velocity of erythrocytes, 
θ is the angle between the axis of the beam and direction of flow (insonation angle), and c is the 
velocity of sound in blood (approximately 1540 m/s; Radegran, 1999; Wood, 2010). The 
insonation angle must be below 60° for accurate assessment of blood flow measurements. 
Angles greater than 60° will provide an amplified error when blood flow is calculated from the 
velocity profile.  
 The strength of Doppler ultrasound is that it provides a continuous, non-invasive estimate 
of beat-to-beat blood velocity (Shoemaker, 1996). Coupled with the cross-sectional area of the 
examined artery (e.g. brachial artery), limb blood flow can be calculated at rest, at onset of and 
during submaximal exercise, as well as post-exercise (Radegran, 1999). Additionally, Doppler 
ultrasound during rest and exercise has proven to be a reproducible and reliable modality to 
assessing blood flow control (Shoemaker, 1996).  
 
2.5 Brachial Artery Pressure Measurements 
 
 The Finometer
TM
 allows for the continuous, non-invasive collection of arterial pressure. 
Arterial pressures are obtained from a cuff that is placed around the intermediate phalanx of the 
middle finger. Specifically, the Finometer
TM
 calculates arterial pressure via the volume clamp 
technique and the physiocal set-point criteria (Guelen, 2003; & Guelen, 2008). However, as 
mentioned previously, blood pressure and pulse shape vary within the arterial tree. Thus, a 
brachial pressure waveform must be remodeled from the pressure waveform obtained in the 
finger (Bogert, 2004). The reconstructed brachial artery pressures are sensitive and accurate 
representations of brachial artery pressures in a supine position (Guelen, 2003; Schutte, 2003; 
Guelen, 2008). Additionally, our laboratory has demonstrated the accuracy of the calculated 
brachial artery pressure waveform using handheld tonometry (Zamir, 2007).  
 
  
14 
 
 
 
Chapter 3 
 
3. Methodology 
 
3.1 Ethical Approval 
 
 Participants from Western University and the public volunteered to take part in this study 
after receiving written and verbal details of the experimental procedures and signing consent 
forms approved by The Human Subjects Research Ethics Board at Western University. 
Participants were made aware that they could withdraw from the study at any time without 
consequence. 
 
3.2 Subjects 
 
A total of 80 Caucasian adults between the ages of 18 and 30 were genotyped to 
determine whether they were carriers of the AC6 S674 allele. A 10 mL blood sample was drawn 
from the antecubital fossa with the participant in a supine position. The blood sample was put on 
ice and transported to the Blackburn Cardiovascular Genetics Laboratory, Western University for 
extraction of white blood cells and genotyping.  Data on height, weight, and waist circumference 
were also obtained. Exclusion criterion included: previously reported cardiovascular, metabolic, 
or neurological disease; diabetes; administered prescribed medication that affects autonomic or 
cardiovascular function (with the exclusion of oral contraceptives); urinary or digestive 
problems; Raynaud’s syndrome, or; pregnancy. 
Of the 80 individuals screened, four (two males) participants were identified as 
heterozygous carriers for the AC6 S674 variant (henceforth referred to as the AC6 variant 
group). An additional six participants (three male) were age-matched from the pool of non-
variant carriers and served as a control group. Oral contraceptive use was documented; however 
no standard of timing in regards to menstrual cycle was measured. There were no perceivable 
differences between males and females once data was normalized and were therefore pooled. 
 
3.3 Genomic DNA Analysis 
 
Genomic DNA was extracted from whole blood using the Puregene DNA isolation kit 
(Gentra Systems, QIAGEN Inc, Mississauga, ON, Canada). Genotyping was performed via 
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exon-specific polymerase chain reaction (PCR) amplifications in the AC6 gene (Gros, 2005). 
PCR amplifications were completed in 30µL mixtures containing 32pmol of each primer; 0.2mM 
of each dATP, dCTP, dGTP, DTTP, and; 1.5mM MgCl2, 50mM KCl, 20mM Tris-HCl (pH 8.4), 
1.0 units of Taq platinum DNA polymerase (Invitrogen; Life Technologies Corporation, 
Carlsbad, California). Thirty cycles were conducted that contained: denaturation at 95°C, 
annealing at 60°C ,and extension at 72°C for 30s each; followed by a final extension for 7mins at 
72°C and cooling to 4°C. PCR products were purified with CIP/Exol (New England Biolabs, 
Pickering, Ontario) and sequenced on an ABI 3730 DNA Analyzer (Applied Biosystems, Foster 
City, California). Analysis of DNA sequences was measured by Seq Scape v2.6 (Applied 
Biosystems, Foster City, California).  
 
3.4 Experimental Design 
  
3.4.1 Hemodynamics 
 
In the follow-up study to assess cardiovascular control of AC S674, all measurements 
were performed with participants in a quiet, darkened room with constant temperature. 
Participants reported to the laboratory after a three hour fast and having abstained from caffeine, 
alcohol, and exercise for a period of 12 hours. A venous catheter was inserted into a large vein in 
the antecubital fossa of the right arm for delivery of pharmacological agents. Heart rate was 
recorded via a three lead ECG (Pilot-9200; Colin Medical Instruments, San Antonio, Texas). 
Continuous blood pressure measures were obtained from the middle finger of the left hand via 
finger cuff plethysmography (FMS Finometer; Finapres Medical Systems, Arnheim, 
Netherlands).  Finometer measurements of the middle finger were recalculated to produce 
brachial artery blood pressure waveforms of the left arm(Schutte, 2003; Bogert, 2004; Bogert & 
van Lieshout, 2005). Calculated brachial artery waveforms have previously been shown to 
accurately represent true waveforms as assessed by applanation tonometry(Zamir, 2007). 
Additionally, brachial blood pressure values were matched to manual sphygmomanometer 
measurements of the right arm for consistency. 
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3.4.2 Ultrasound 
  
Ultrasound imaging of the ascending aorta and brachial arteries was performed 
simultaneously with participants in the supine position. Blood flow velocity of the ascending 
aorta (via the suprasternal notch) was assessed by pulsed-wave Doppler ultrasound (2MHz; 
Vingmed CFM 750; GE Medical Systems Canada, Mississauga, Canada). Brachial artery 
diameters of the right and left arm were obtained using two-dimensional ultrasound imaging 
(10MHz; B-Mode ultrasound: GE System 5; GE Healthcare), while pulsed-wave Doppler 
ultrasonography (4.7 MHz; GE System 5; GE Healthcare) measured mean blood flow velocities.  
All analog signals of hemodynamic and ultrasound data were sampled at 1000Hz and 
collected online by the PowerLab data acquisition system (PowerLab 6; ADInstruments, Castle 
Hill, Australia). Participants lay supine for a period of 10 minutes before commencement of data 
collection.  
 
3.4.3 Handgrip Exercise 
 
 Baseline measurements were recorded for 5minutes, followed by three 1minute handgrip 
bouts (at 20, 40, and 60% of maximum volitional contraction [MVC]) with 3 minutes between 
each bout. Measures of maximal voluntary contraction force were performed 10 minutes prior to 
the commencement of baseline measures. The 1 minute bouts of handgrip exercise consisted of a 
2 second exercise-relaxation protocol (Figure 3.1). The order of 20 and 40% handgrips was 
assigned randomly determined by a coin flip while the 60% handgrip was always conducted last. 
The 60% handgrip protocol was performed last to minimize the effect of muscle fatigue on 
forearm blood flow. A standardized Borg scale was used to assess perceived exertion after each 
exercise bout. 
 
 
 
 
 
 
 
 
Figure 3.1 Handgrip exercise for 20% MVC indicates the 2 second intermittent contraction-
relaxation protocol with Doppler ultrasound collected throughout.  
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3.4.4 Cardiac and Vasomotor Control 
 
 Previously, venous infusion of isoproterenol has elicited a greater venous dilation in 
carriers of the AC S674 variant (Gros, 207). To assess the function of AC S674 on cardiac and 
vasomotor control, isoproterenol and propranolol were infused separately through a venous 
catheter. Isoproterenol is a non-specific beta-adrenergic agonist and propranolol is a non-specific 
beta-adrenergic antagonist. As such, venous infusion of isoproterenol and propranolol allows for 
cardiac and vascular smooth muscle responses to occur. Baseline measurements were recorded 
for 1minute, followed by two 5 minute infusions of isoproterenol (0.01 and 0.02 µg·kg
-1
·min
-1
 
diluted in 5% dextrose). Infusion was stopped, and heart rate and blood pressure were monitored 
until they returned to pre-isoproterenol baseline. Isoproterenol doses of 0.01 and 0.02 µg·kg
-
1
·min
-1
 increase heart rate and stroke volume in health y individuals (Edgell, 2007) and these 
doses were used here to study both the cardiac and vascular response in both wild type and 
ACS674 variants. Isoproterenol infusion was followed by a single dose propranolol infusion (0.1 
mg·kg
-1
 diluted in 0.9% saline) of 10 minutes. Measurements were collected for 1 minute pre 
and 5 minutes post-propranolol infusion. Due to the long half-life of propranolol, a single dose 
was infused to observe alterations to cardiac and vasomotor function from baseline. A separate 
saline trial (0.9% NaCl) was randomly inserted before, between, or after the isoproterenol 
infusions via random selection.  
 
3.5 Data Analysis 
 
3.5.1 Stroke Volume 
 
 Aortic diameters were measured (Vivid i; GE Healthcare, Mississauga, Canada) and 
analyzed using EchoPac Dimension software. Stroke volume was calculated as:        
  , where SVV is the mean blood flow velocity in the ascending aorta, and AA is the aortic area. 
Cardiac output was calculated (CO = HR × SV) and normalized to body surface area (BSA) using 
the Du Bois formula (BSA = 0.007184 × W
0.425
 × H
0.725
). Subsequently, mean arterial pressure 
(MAP = diastolic blood pressure + 1/3 pulse pressure), and systemic vascular conductance (SVC 
= CO/MAP) were calculated.  
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3.5.2 Forearm Blood Flow 
 
 Brachial artery diameters were stored and measured digitally (EchoPac Dimension 
software). Three measurements were averaged to acquire a mean value during systole and 
diastole to determine brachial artery diameters. Brachial blood flow was calculated as: Flow 
(ml/min) =               , where v is the blood velocity, and r is the brachial artery radius 
(r = (2/3diastolic diameter + 1/3 systolic diameter)/2) (Radegran, 1997). Blood flow values were 
averaged for 10 cardiac cycles at baseline and 2-3 cardiac cycles during the relaxation phases of 
handgrip exercise and again immediately post-exercise. Forearm vascular conductance (FVC) 
was calculated as limb blood flow divided by MAP. Forearm volume was calculated using the 
equation for a truncated cone (V = h[C1
2
 + C1C2 + C2 
2
] /12π), where V is the volume of the 
forearm, C1 is the circumference of the wrist, C2 is the circumference of the widest part of the 
forearm at the elbow, and h is the distance between circumference measurements (Taylor, 2006). 
Thus, FBF and FVC were normalized to 100 ml of tissue.  
 
3.5.3 Vascular Bed Mechanics 
 
 A modified three-element lumped Windkessel model was utilized to quantify forearm 
vascular bed mechanics. This model included determination of vascular compliance (C), 
viscoelasticity (K) and inertance (L). The value of R was obtained by simultaneously measuring 
mean pressure and mean flow at the point of entry to the vascular bed (23). The values of C, K, 
and L are calculated from simultaneous measurement of oscillatory pressure and flow at the 
vascular bed entry point (23). For a given set of values (C, K, and L), the model predicts a flow 
wave that would be produced by a measured pressure wave during pulsatile flow (22). 
Additionally, compliance was normalized to 100 ml of forearm tissue.  
 Ten consecutive cardiac cycles at baseline and during isoproterenol (5mins) and 
propranolol (5, 10, and 15mins) were analysed. Data (ECG, brachial pressure, and left arm 
brachial flow) were stored and saved in MATLAB format for RCKL program analysis. The 
blood pressure and flow waveforms were time-aligned to produce the estimated flow waveform 
with the lowest error. 
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3.5.4 Statistical Analysis 
 
 Baseline hemodynamic and vascular mechanic data were determined by comparing the 
mean values of the measured variables using an independent samples t-test. Additionally, the 
total change of forearm blood flow (ΔFBF) and forearm vascular conductance (ΔFVC) from rest 
to exercise termination was assessed using an independent samples t-test. Moreover, to assess the 
changes in forearm blood flow during rhythmic handgrip exercise (handgrip × group), a split-plot 
ANOVA was applied for each exercise intensity.  
To determine the effect of isoproterenol (dose × group) on cardiac and vascular 
measurements, a split-plot (mixed design) analysis of variance (ANOVA) was used. A 
Greenhouse-Geisser correction was used to account for violations of sphericity when applicable. 
A significant interaction effect prompted the analysis of simple main effects to identify 
univariate differences between groups. The total response (Δ = 15 minutes - baseline) in 
hemodynamic and vascular mechanic data during propranolol infusion was assessed using an 
independent samples t-test. The level of significance for statistical tests was set at p < 0.05. All 
data are presented as means ± standard deviation. 
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Chapter 4 
 
4. Results 
 
 In three separate instances, participant data were excluded from the final analysis of 
cardiac and forearm vasomotor control. Firstly, one control participant failed to comply with the 
handgrip protocol. Data from this participant were not included in the final calculation of 
handgrip responses in the control group. Second, a separate control participant was excluded 
from the analysis of forearm vascular bed mechanics because the data were statistically an 
outlier. Third, a participant in the AC S674 group did not undergo the pharmacological protocol 
because of noticeable baseline bradycardia (33 bpm) causing the concern on the part of the 
anesthetist to infuse the pharmacologic agents.  
 
4.1 Baseline Assessment 
 
4.1.1 Anthropometric Measurements 
 
 There were no significant differences in anthropometric measurements between groups at 
baseline (Table 4.1).  However, aortic diameter was significantly smaller in the AC S674 group. 
 
Table 4.1 Anthropometric Measurements 
 Control (n = 6) AC S674 (n = 4) 
Age (years) 25 ± 2 25 ± 4 
Height (cm) 168 ± 6 177 ± 6 
Weight (kg) 63 ± 12 69 ± 2 
BMI (kg·m
2
) 22.1 ± 3.2 22.3 ± 1.1 
Waist Circumference (cm) 84 ± 7 86 ± 5 
Aortic Diameter (cm) 2.8 ± 0.3 2.1 ± 0.2 * 
*Significantly different from controls (p < 0.05). Values are mean ± standard deviation. 
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4.1.2 Hemodynamic Measurements 
 
 Hemodynamic measurements at baseline were not different during saline infusion. As 
such, non-saline values are expressed in Table 4.2. Stroke volume, cardiac output, DBP, MAP 
and SVC were decreased in the AC S674 variant group compared to controls (p < 0.05). 
Additionally, PP was increased in the AC S674 variant group compared to controls (p < 0.05).  
 
Table 4.2 Baseline hemodynamic characteristics 
 Control (n = 6) AC S674 (n = 4) 
HR (beats·min
-1
) 59 ± 5 48 ± 14 
SV (ml·min
-1
) 112 ± 27 51 ± 13
t
 * 
CO (L·min
-1
·m
2
) 3.96 ± 1.26 1.42 ± 0.21
t
 * 
SBP (mm Hg) 114 ± 8 114 ± 3 
DBP (mm Hg) 77 ± 4 62 ± 6 * 
PP (mm Hg) 37 ± 7 52 ± 5 * 
MAP (mm Hg) 89 ± 5 79 ± 4 * 
SVC (L·min
-1
·m
2
) 0.045 ± 0.018 0.017 ± 0.002
t
 * 
FBF (ml·min
-1
·100ml
-1
) 2.21 ± 0.59 2.76 ± 0.83 
FVC (ml·min
-1
·100ml
-1
·mm Hg
-1
) 0.0248 ± 0.007 0.0345 ± 0.010 
HR, heart rate; SV, stroke volume; CO, cardiac output; SBP, systolic blood pressure; DBP, 
diastolic blood pressure; PP, pulse pressure; MAP, mean arterial pressure; SVC, systemic 
vascular conductance; FBF, forearm blood flow; FVC, forearm vascular conductance. 
t 
indicates 
sample size of three. Values are mean ± standard deviation. 
*Significantly different from controls (p < 0.05).  
 
4.1.3 Forearm Vascular Bed Mechanics 
 
 The values of resistance, viscoelasticity and inertia were not significant between the AC 
S674 variant group and controls. However, compliance was lower in the AC S674 variant group 
compared to controls (p < 0.05; Table 4.3). 
 
Table 4.3 Baseline forearm vascular bed mechanics  
 Control (n = 5) AC S674 (n = 4) 
R (mm Hg·ml
-1
·min
-1
) 5.44 ± 1.46 4.55 ± 1.79 
C (ml·mm Hg
-1
·100ml
-1
) 9.2 × 10
-4 
± 2.0 × 10
-4
 6.8 × 10
-4
 ± 6.1 × 10
-5
 * 
K (mm Hg·ml
-1
·min
-1
) 4.9 × 10
-2 
± 2.8 × 10
-2
 8.7 × 10
-2 
± 5.1 × 10
-2
 
L (mm Hg·ml
-1
·min
2
) 1.4 × 10
-5 
± 1.1 × 10
-5
 1.6 × 10
-5 
± 1.5 × 10
-5
 
R, resistance; C, compliance; K, viscoelasticity; L, inertia. Values are mean ± standard deviation. 
*Significantly different from controls (p < 0.05). 
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4.2 Handgrip Exercise 
 
4.2.1 Forearm Blood Flow 
 
 There was no significant group x handgrip interaction effect on FBF. FBF increased 
significantly in response to handgrip exercise. This main effect was observed for all levels of 
handgrip intensity (20% MVC: p < 0.05, Figure 4.1A; 40% MVC: p < 0.05, Figure 4.3 A; 60% 
MVC; p < 0.05, Figure 4.5 A).  
 The change in FBF from pre- to post-handgrip exercise was not significant between AC 
S674 and control groups at each handgrip intensity (p = NS; Figures 4.2, 4.4, and 4.6).  
 
4.2.2 Mean Arterial Pressure 
 
 There was no significant group x handgrip interaction effect on MAP. MAP remained 
constant throughout all levels of handgrip exercise (p = NS). However, MAP was greater in 
controls throughout handgrip exercise at 20 and 40% MVC. This main effect of group was 
observed at 20 and 40% MVC (20% MVC:  p < 0.05, Figure 4.1 B; 40% MVC: p < 0.05, Figure 
4.3 B), but not 60% MVC (p = NS; Figure 4.5 B).  
 
4.2.2 Forearm Vascular Conductance 
 
 There was no significant group x handgrip interaction effect on FVC. FVC increased 
significantly in response to handgrip exercise. This main effect was observed for all levels of 
handgrip intensity (20% MVC: p < 0.05, Figure 4.1 C; 40% MVC: p < 0.05, Figure 4.3 C; 60% 
MVC: p < 0.05, Figure 4.5 C).  
 The change in FVC from pre- to post-handgrip exercise was not significant between AC 
S674 and control groups at each handgrip intensity (p = NS; Figures 4.2, 4.4 and 4.6).  
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Figure 4.1 Forearm blood flow (FBF), mean arterial pressure (MAP), and forearm vascular 
conductance (FVC) responses to 20% MVC handgrip exercise in control (n = 5) and AC S674 (n 
= 4). A. Main effect of handgrip on FBF (p < 0.05); B. Main effect of group on MAP (p < 0.05); 
C. Main effect of handgrip on FVC (p < 0.05). Values are mean ± standard deviation. 
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Figure 4.2 ΔFBF (top) and ΔFVC (bottom) to 20% handgrip exercise in control (n = 5) and AC 
S674 (n = 4). No significant differences occurred between groups for either FBF or FVC (p = 
NS). Values are mean ± standard deviation. 
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Figure 4.3 Forearm blood flow (FBF), mean arterial pressure (MAP), and forearm vascular 
conductance (FVC) responses to 40% MVC handgrip exercise in control (n = 5) and AC S674 (n 
= 4). A. Main effect of handgrip on FBF (p < 0.05); B. Main effect of group on MAP (p < 0.05); 
C. Main effect of handgrip on FVC (p < 0.05). Values are mean ± standard deviation. 
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Figure 4.4 ΔFBF (top) and ΔFVC (bottom) to 40% handgrip exercise in control (n = 5) and AC 
S674 (n = 4). No significant differences occurred between groups for either FBF or FVC (p = 
NS). Values are mean ± standard deviation. 
  
27 
 
 
 
 A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 B. 
 
 
 
 
 
 
 
 
 
 
 
 
 C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Forearm blood flow (FBF), mean arterial pressure (MAP), and forearm vascular 
conductance (FVC) responses to 60% MVC handgrip exercise in control (n = 5) and AC S674 (n 
= 4). A. Main effect of handgrip on FBF (p < 0.05); B. No significant interaction or main effects 
observed for MAP (p = NS); C. Main effect of handgrip on FVC (p < 0.05). Values are mean ± 
standard deviation.  
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Figure 4.6 ΔFBF (top) and ΔFVC (bottom) to 60% handgrip exercise in control ( n = 5) and AC 
S674(n = 4). No significant differences occurred between groups for either FBF or FVC (p = 
NS).  Values are mean ± standard deviation. 
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4.3 Cardiac and Vasomotor Control 
 
4.3.1 Heart Rate 
 
 There was no significant group x dose interaction effect of isoproterenol on heart rate. 
However, there was a main effect of isoproterenol dose on HR. Specifically, HR increased across 
isoproterenol doses (p < 0.05; Figure 4.7 C). 
The change in heart rate was not significantly different between AC S674 and control 
groups throughout propranolol infusion (Figure 4.14 A). 
 
4.3.2 Stroke Volume 
 
 There was no significant group x dose interaction effect of isoproterenol on stroke 
volume. However, stroke volume was increased in controls compared to AC S674 (p < 0.05, 
Figure 4.8 C).  
The change in stroke volume was not significantly different between AC S674 and 
control groups throughout propranolol infusion (Figure 4.14 B). 
 
4.3.3 Cardiac Output 
 
 There was no significant group x dose interaction effect of isoproterenol on cardiac 
output. However, there was a main effect of isoproterenol dose on CO. Specifically, CO 
increased across isoproterenol doses (p < 0.05; Figure C). There was also a main effect of group 
on cardiac output across isoproterenol doses (controls > AC S674; p < 0.05, Figure 4.9 C).  
The change in cardiac output was not significantly different between AC S674 and 
control groups throughout propranolol infusion (Figure 4.14 C). 
 
4.3.4 Mean Arterial Pressure 
 
There was no significant group x dose interaction effect of isoproterenol on mean arterial 
pressure. Additionally, mean arterial pressure was not significantly different across isoproterenol 
doses (p = NS; Figure 4.10 C).  
The change in mean arterial pressure was not significantly different between AC S674 
and control groups throughout propranolol infusion (Figure 4.15 A). 
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4.3.5 Systemic Vascular Conductance 
 
 There was no significant group x dose interaction effect of isoproterenol on systemic 
vascular conductance. Additionally, systemic vascular conductance was not significantly 
different across isoproterenol doses (p = NS; Figure 4.11 C).  
The change in systemic vascular conductance was not significantly different during 
propranolol infusion (p = NS; Figure 4.15 B) 
 
4.3.6 Forearm Blood Flow 
 
There was no significant group x dose interaction effect of isoproterenol on forearm 
blood flow. However, there was a main effect of isoproterenol dose on forearm blood flow. 
Specifically, forearm blood flow increased across isoproterenol doses (p < 0.05, Figure 4.12 C). 
The change in forearm blood flow was not significantly different during propranolol 
infusion (p = NS; Figure 4.16 A). 
 
4.3.7 Forearm Vascular Conductance 
 
 There was no significant group x dose interaction effect of isoproterenol on forearm 
vascular conductance. However, there was a main effect of isoproterenol dose on forearm 
vascular conductance. Specifically, forearm vascular conductance increased across isoproterenol 
doses (p < 0.05, Figure 4.13 C). 
The change in forearm vascular conductance was not significantly different during 
propranolol infusion (p = NS; Figure 4.16 B). 
 
4.3.8 Forearm Vascular Bed Mechanics 
 
 There were no significant group x dose interaction effect of isoproterenol on resistance, 
compliance, viscoelasticity, or inertia. However, resistance decreased across isoproterenol doses 
(p < 0.05, Figure 4.17 A). Conversely, compliance increased across isoproterenol doses (p < 
0.05, Figure 4.17 B). Additionally, there was a main effect of group on compliance (p < 0.05, 
Figure 4.17 B). Specifically, compliance was lower in AC S674 compared to controls. 
Viscoelasticity was not significantly different between groups and across isoproterenol doses 
(Figure 4.17 C). There was a main effect of isoproterenol dose on inertia (p < 0.05, Figure 4.17 
D). Propranolol infusion did not have a significant effect on ΔR, ΔC, ΔK, or ΔL (p = NS; Figure 
4.18 and Figure 4.19).
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Figure 4.7 Heart rate (HR) responses to isoproterenol. A. HR response to first isoproterenol dose (0.01µg·kg
-1
); B. HR response to 
second isoproterenol dose (0.02µg·kg
-1
); C. Maximum HR values obtained during isoproterenol dose one and two. A main effect of 
isoproterenol dose on HR occurred (C; p < 0.05; controls: n = 6; AC S674: n = 3). Values are means ± standard deviation.   
32 
 
 
 
 
 
 
 
 
 
 
 
A.             B.            C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8 Stroke volume (SV) responses to isoproterenol. A. SV response to first isoproterenol dose (0.01µg·kg
-1
); B. SV response to 
second isoproterenol dose (0.02µg·kg
-1
); C. Maximum stroke volume values obtained during isoproterenol dose one and two. A main 
effect group on SV occurred (C; p < 0.05; controls: n = 6; AC S674: n = 3). Values are means ± standard deviation. 
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Figure 4.9 Cardiac output (CO) responses to isoproterenol. A. CO response to first isoproterenol dose (0.01µg·kg
-1
); B. COresponse 
to second isoproterenol dose (0.02µg·kg
-1
); C. Maximum CO values obtained during dose one and two. A main effect of isoproterenol 
dose on CO occurred (C; p < 0.05; controls: n = 6; AC S674: n = 3). Values are means ± standard deviation. 
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Figure 4.10 Mean arterial pressure (MAP) responses to isoproterenol. A. MAP response to first isoproterenol dose (0.01µg·kg
-1
); B. 
MAP response to second isoproterenol dose (0.02µg·kg
-1
); C. Maximum MAP values obtained during dose one and two. There was 
no effect of isoproterenol dose or group on MAP (C; p = NS; controls: n = 6; AC S674: n = 3). Values are means ± standard deviation. 
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Figure 4.11 Systemic vascular conductance (SVC) responses to isoproterenol. A. SVC response to first isoproterenol dose 
(0.01µg·kg
-1
); B. SVC response to second isoproterenol dose (0.02µg·kg
-1
); C. Maximum SVC values obtained during dose one and 
two. There was no effect of isoproterenol dose or group on SVC (C; p = NS; controls: n = 6; AC S674: n = 3). Values are means ± 
standard deviation. 
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Figure 4.12 Forearm blood flow (FBF) responses to isoproterenol. A. FBF response to first isoproterenol dose (0.01µg·kg
-1
); B. FBF 
response to second isoproterenol dose (0.02µg·kg
-1
); C. Maximum FBF values obtained during dose one and two. A main effect of 
isoproterenol dose on FBF occurred (C; p < 0.05; controls: n = 6; AC S674: n = 3). Values are means ± standard deviation. 
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Figure 4.13 Forearm vascular conductance (FVC) responses to isoproterenol. A. FVC response to first isoproterenol dose  
(0.01µg·kg
-1
); B. FVC response to second isoproterenol dose (0.02µg·kg
-1
); C. Maximum values obtained during dose one and two. A 
main effect of isoproterenol dose on FVC occurred (C; p < 0.05; controls: n = 6; AC S674: n = 3). Values are means ± standard 
deviation. 
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Figure 4.14 Cardiac responses to propranolol infusion.  Left: time course response, Right: 
change (Δ) from rest to 15 minutes. A. No significant differences between groups on ΔHR; B. 
No significant differences between groups on ΔSV; and C. No significant differences between 
groups on ΔCO (controls: n = 6; AC S674: n = 3). Values are means ± standard deviation. 
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Figure 4.15 Systemic responses to propranolol infusion. Left: time course response, Right: 
change (Δ) from rest to 15 minutes. A. No significant difference between groups on ΔMAP; B. 
No significant difference between groups on ΔSVC (controls: n = 6; AC S674: n = 3). Values are 
means ± standard deviation. 
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Figure 4.16 Forearm vascular responses to propranolol infusion. Left: time course response, 
Right: change (Δ) from rest to 15 minutes. A. No significant difference between groups on 
ΔFBF; B. No significant difference between groups on ΔFVC (controls: n = 6; AC S674: n = 3). 
Values are means ± standard deviation. 
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Figure 4.17 Maximal forearm vascular bed mechanic responses to isoproterenol. A. Main effect 
of isoproterenol on resistance. B. Main effect of isoproterenol on compliance. C. No significant 
effect of isoproterenol or group on viscoelasticity. D. Main effect of isoproterenol on inertia 
(controls: n = 5; AC S674: n = 3). Values are means ± standard deviation. 
 
 
 
 
 
 
42 
 
 
 
 
 
 
 
A.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18 Forearm vascular bed mechanic responses to propranolol. Left: time course 
response, Right: change (Δ) from rest to 15 minutes.  A. No significant difference between 
groups on Δ resistance; B. No significant difference between groups on Δ compliance (controls: 
n = 6; AC S674: n = 3). Values are means ± standard deviation. 
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Figure 4.19 Forearm vascular bed mechanic responses to propranolol. Left: time course 
response, Right: change (Δ) from rest to 15 minutes.  A. No significant difference between 
groups on Δ viscoelasticity; B. No significant difference between groups on Δ inertia (controls: n 
= 6; AC S674: n = 3). Values are means ± standard deviation. 
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Chapter 5 
 
5. Discussion  
 
The purpose of the present study was to identify the role of AC S674 in cardiac and 
vasomotor control. First, compared with non-variant, individuals with AC S674 expressed 
decreased baseline cardiac contractility (SV and CO), altered blood pressure characteristics 
(decreased DBP, MAP; increased PP), decreased forearm vascular bed compliance, and 
increased vasomotor contractile state (decreased SVC). However, neither the systemic nor 
forearm responses to beta-adrenergic activation or blockade, nor the exercise-induced dilation 
during handgrip, were affected by AC S674. Therefore, the major impact of this adenylyl cyclase 
variant appears to affect baseline hemodynamics and not responsiveness to vasoactive stimuli.  
 
5.1 Baseline  
 
The AC S674 genetic variant has been referred to as a hyperfunctional enzyme compared 
to the more common AC A674 genotype (Gros, 2007; Hodges, 2010). As such, it is possible that 
there is increased activity of the AC S674 enzyme and cAMP production at rest. Additionally, 
this increase in AC S674 activity would be expected to promote greater cardiac contractility, 
smooth muscle relaxation, enhanced vasodilation of arteries, decreased vasomotor tone and, 
therefore, increased vascular conductance. However, the results of the current study indicate the 
opposite, as evidenced by decreased cardiac output and vascular bed compliance. 
Blood flow to vascular beds within the human body is determined by perfusion pressure 
(mean arterial pressure) and vascular contractile state (conductance). However, MAP was 
significantly decreased in AC S674 individuals and relied on a reduced SVC to maintain the 
same level of blood flow as controls. The three-fold smaller CO at rest in AC S674 individuals 
was the determining factor of reduced SVC. In turn, the smaller CO was related first to a smaller 
aortic diameter. This is the first report of altered CO and aortic diameter in this variant group and 
suggests that a major impact of AC S674 affects cardiac structure. As this finding was 
unexpected, additional studies are needed to address this important possibility. Further, the 
enhanced PP in this group is consistent with reduced aortic size and indicates an increased 
vascular stiffness of the central arteries. This observation is consistent with the diminished 
compliance of the forearm vascular bed. For reasons that are not known, the intervening brachial 
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artery conductance was not different between groups. Overall, however, the altered cardiac and 
vascular structure appears to be a major outcome in this AC variant.  
The mechanisms mediating this altered structure remain to be determined, but could 
include elevated adrenergic or angiotensin II stimuli. Under baseline conditions, sympathetic 
vasomotor nerves regulate arterial pressure and control the distribution of CO at rest (Dampney, 
2002). It is possible that AC S674 individuals express greater sympathetic tone or increased 
levels of vasoconstrictor metabolites. However, previously observed baseline levels of 
norepinephrine were similar in AC S674 variant individuals and non-variants (Hodges, 2010). 
Additionally, elevated angiotensin II could also affect cardiac and vascular structure and 
mechanics. Importantly, AC S674 carriers were found to have increased levels of circulating 
plasma renin (Hodges, 2010). Renin is a crucial enzyme that regulates the production of 
angiotensin II, a potent vasoconstrictor. In the current study, reduced SVC in AC S674 could be 
a reflection of the chronic effects of increased renin activity, leading to enhanced aldosterone-
mediated effects on blood volume in addition to possible increased ambient angiotensin II-
mediated effects (Hodges, 2010).  
In the same way that vascular conductance (or resistance) influences steady state flow, a 
change in compliance affects the impedance of the vascular bed in pulsatile flow. Additionally, 
arterial compliance is influenced by vascular smooth muscle contractility and is an indicator of 
vasomotor control (Zamir, 2007). In the present study, baseline forearm vascular bed compliance 
was lower in AC S674 individuals. This reduction in compliance may be related to increased 
vasomotor tone (Frances, 2011). However, compliance represents the elastic ability of the 
arterial wall and, is therefore associated with elastin fibres (Zamir, 2009). Whether this 
diminished compliance is due to increased neurogenic vasoconstrictor effects or altered vascular 
stiffness remains to be determined.  
The AC S674 group consisted of young, physically active individuals free of 
cardiovascular abnormalities. It is possible that the cardiac data may vary from general 
population due to above-average fitness levels of participants in both groups. However, the long-
term effect of chronically reduced SVC and diminished vascular bed compliance is a point of 
interest for continued study for this group. Furthermore, AC S674 individuals expressed lower 
DBP and greater PP compared to controls. These two variables are the preeminent markers for 
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vascular stiffening. Thus, further research is required to determine the cause of increased 
vascular resistance in AC S674 individuals. 
 
5.1.1 Methodological Considerations  
 
The hemodynamic profile of the AC S674 group was significantly different compared to 
controls. The AC S674 group expressed a significantly lower cardiac output and reduced SVC. 
Specifically, the decreased stroke volume in AC S674 was the primary cause for reduced cardiac 
output as heart rate was similar between groups. The difference in stroke volume between groups 
may be due to a decreased aortic diameter in AC S674 compared to controls. It is not known if 
this difference in aortic diameter is a characteristic of the AC S674 population as this is the first 
study to measure stroke volume velocity in this cohort. Previously, cardiac output collected via 
Finometer has been shown to be increased in AC S674 compared to controls (Hodges, 2010). In 
the present study, cardiac output values were based on Doppler ultrasound measures. However, 
to contrast the current data with those measured previously, the cardiac output feature of the 
Finometer was also measured. This value of cardiac output was similar between groups, 
contrasting with the Doppler data. However, calculation of cardiac output from the Finometer 
uses the patented ModelFlow algorithm that predicts cardiac stroke volume centred on a transfer 
function-based calculation of the aortic pulse pressure assuming a level of aortic compliance 
based on age and sex (Pulse Pressure = Stroke Volume/Compliance). An aorta with greater than 
expected stiffness will increase the calculated PP and lead to a SV that is erroneously high. This 
may be the case in the current study.  
 
5.2 Handgrip Exercise  
 
To our knowledge, this study was the first to examine the effect of adenylyl cyclase on 
different levels of submaximal dynamic exercise in humans. In the present study, the hyperemic 
response to 20, 40 and 60% dynamic handgrip exercise were not significantly different in AC 
S674 and control groups. Specifically, there was no significant difference in either FBF or FVC 
kinetics during handgrip exercise at the various intensities. The total response of ΔFBF and 
ΔFVC were similar between groups as well. Thus, the genetic variant AC S674 does not produce 
enhanced vasodilatory effects in response to dynamic exercise. These observations stand in 
contrast to those observed earlier by Hodges . (2010) who also used handgrip exercise. However, 
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in that earlier study, the flow was measured during a five second recovery period after a 5 second 
handgrip. The regulation of post-exercise blood flow differs from that during more rhythmic 
contractions(Shoemaker, 1997; Brock, 1998). Thus, it appears that the AC S674 variant may 
exert its vascular effects on the recovery phase of exercise.  
Adenosine and prostaglandins stimulate adenylyl cyclase to induce vascular smooth 
muscle relaxation and arterial vasodilation during exercise (Joyner, 2007; Clifford, 2011). 
Adenosine has been a leading candidate for metabolic vasodilation because it is a potent 
vasodilator released from contracting skeletal muscle (Radegran, 2001). As well, arterial infusion 
of prostacyclin (a powerful vasodilating prostaglandin) increases blood flow in the human 
forearm (Stiegler, 1988). However, recent evidence in humans indicates that not all people 
respond to adenosine and that the overall contribution of prostaglandins to exercise blood flow 
control remains small (Shoemaker, 1996; Martin, 2007; Joyner, 2007). In the present study, 
blood flow responses were similar in AC S674 and control groups. As such, it is hypothesized 
that these metabolites did not increase contributions of AC S674 on vasodilation. Further 
research must be conducted to assess the functionality of these metabolites on the AC S674 
enzyme during exercise. 
The requirements of skeletal muscle blood flow directly correlate to metabolic demand. 
In addition to adenosine and prostaglandins, nitric oxide, potassium and acetylcholine spillover 
contribute to vasodilation in response to active skeletal muscle contraction (Clifford, 2004; 
Joyner 2007). This overlap in metabolic pathways makes it difficult to tease out the vasodilator 
effects of any individual mechanism, such as adenylyl cyclase. Specifically, neither nitric oxide 
nor acetylcholine individually affects the magnitude or rate of increase in FBF exercise 
(Shoemaker, 1997). Thus, AC S674 is not the sole determinant of increased skeletal muscle 
blood flow during dynamic exercise, as other pathways may up or down regulate their activity to 
meet the metabolic requirements of the exercising muscle.  
Overall, the current data suggest that the AC S674 enzyme does not exhibit increased 
vasodilator effects in response to submaximal dynamic exercise. The similar FBF and FVC 
responses in both AC S674 individuals and controls can be explained by the classical “metabolic 
milieu” response to exercise. Additional research must be conducted to parse out the overlapping 
effects of vasodilator metabolites. 
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5.3 Beta-adrenergic Control  
 
Isoproterenol is a non-selective beta-adrenergic agonist that exerts potent stimulation of 
β1 and β2 receptors. In the current study, isoproterenol infusion produced significant increases in 
HR and CO in both AC S674 and control groups. However, the presence of AC S674 did not 
provide an increased cardiac response to isoproterenol infusion. The positive chronotropic effects 
of isoproterenol on the heart are consistent with previously reported results in supine humans 
(Gortex, 1961). To our knowledge, this was the first study to examine the beta-adrenergic 
stimulation of AC S674 in the heart.  
Intravenous infusion of isoproterenol primarily elevates FVC in skeletal muscle (Harman 
& Limbird, 1996). Forearm vascular bed conductance and compliance increased in both groups 
during isoproterenol infusion. These alterations to forearm vascular bed mechanics are indicative 
of vascular smooth muscle relaxation. However, FBF and FVC were similar in both groups. 
Thus, the AC S674 enzyme did not appear to present increased levels of vasodilation in response 
to beta-adrenergic activation.  
The above results do not support the hypothesis that this adenylyl cyclase variant would 
exert differential beta-adrenergic control of cardiac or vascular function in response to excitatory 
or inhibitory stimuli. The determinants of impact for this enzyme over baseline hemodynamics, 
but not stimulation-induced changes remain to be determined. Previously, others have observed 
differences in venous vasomotor control in this AC variant group (Gros, 2007). However, arterial 
and venous smooth muscle responses to beta-adrenergic stimulation are not identical (Stein, 
1997). Additional studies examining local artery blood flow and vascular conductance responses 
to beta-adrenergic control are warranted.  
 
5.4 Limitations  
 
The focal limitation of the present study is the small sample size of the AC S674 group. 
A total of 80 individuals were recruited and analyzed for DNA sequencing. Two participants 
were known carriers of the AC S674 variant from previous studies. Therefore, the AC S674 
variant prevalence was 2.5% in the current study population compared to a previously reported 
7% frequency (Gros, 2005). Due to time constraints and limited resources it was not possible to 
identify more carriers for study participation. However, using a two-tailed t-test, p < 0.05, Power 
49 
 
 
 
of 0.80, and effect size of 2.47 describing the difference in SVC between groups, a minimum of 
four individuals per group is necessary to replicate this outcome. Therefore, the small sample 
size used in this study is sufficient to achieve statistical significance.  
Furthermore, it appears that a more comprehensive analysis of the endocrinological and 
visceral hemodynamic control is needed to fully characterize the impact of the AC S674 variant 
in humans. It would seem important that future studies obtain resting muscle sympathetic nerve 
activity (MSNA) in addition to epinephrine, norepinephrine, and plasma renin activity, 
angiotensin II, and vasopressin levels to obtain true values of vasomotor tone in AC S674 
individuals.  
 
5.5 Conclusion and Perspective  
 
The results of the current study indicate that expression of the dysfunctional genetic 
variant AC S674 has profound effects on systemic hemodynamics. At rest, AC S674 individuals 
have decreased SVC and vascular bed compliance indicative of elevated vasomotor tone and/or 
remodeling. Chronic elevation in vascular contractile state may result in vascular stiffening and 
enhanced pulse pressures with detrimental long-term consequences for cardiovascular health. 
Specifically, genetic variants of beta-adrenergic receptors and  G-proteins are associated with the 
development of hypertension(Felder, 2002; Feldman, 2006). Coupled with the results of the 
current study, adenylyl cyclase and cAMP production appear to be important factors in the 
regulation of cardiovascular health.   
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Appendices 
 
Appendix 1A: 20% handgrip exercise 
Variable F Value η2 Significance 
FBF (ME HG) F(3, 21) = 27 0.37 p < 0.001 
FVC (ME HG) F(3, 23) = 30 0.47 p < 0.001 
MAP (ME group) F(1, 7) = 6 0.43 p = 0.042 
ME HG, main effect of handgrip; ME group, main effect of group 
 
Appendix 1B: 40% handgrip exercise 
Variable F Value η2 Significance 
FBF (ME HG) F(3, 20) = 101 0.67 p < 0.001 
FVC (ME HG) F(3, 21) = 121 0.75 p < 0.001 
MAP (ME group) F(1, 7) = 6 0.41 p = 0.044 
ME HG, main effect of handgrip; ME group, main effect of group 
  
Appendix 1C: 60% handgrip exercise 
Variable F Value η2 Significance 
FBF (ME HG) F(3, 18) = 89 0.71 p < 0.001 
FVC (ME HG) F(3, 19) = 86 0.75 p < 0.001 
ME HG, main effect of handgrip 
 
Appendix 2: Isoproterenol dose response 
Variable F Value η2 Significance 
HR (ME dose) F(2,14) = 8 0.32 p = 0.003 
SV (ME group) F(1, 7) = 48 0.85 p < 0.001 
CO (ME dose) F(2, 14) = 5 0.08 p = 0.021 
CO (ME group) F(1, 7) = 6 0.38 p = 0.040 
FBF (ME dose) F(2,11) = 18 0.44 p < 0.001 
FVC (ME dose) F(2,11) = 15 0.44 p < 0.001 
 
Appendix 3: Manual Blood Pressure Data 
 Control (n = 6) AC S674 (n = 4) 
SBP (mm Hg) 114 ± 10 116 ± 2 
DBP (mm Hg) 76 ± 6 71 ± 10 
Values are mean ± standard deviation. 
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